An Epidemiological Update on COVID -19

Immunogenicity of SARS CoV-2 Vaccine

Author(s): B. Prabha*, G. Kalaiarasi and B. Keerthana

Pp: 63-76 (14)

DOI: 10.2174/9789815050325122010012

* (Excluding Mailing and Handling)


At present, we are in a crucial situation to find out and understand the immune response for severe acute respiratory syndrome coronavirus inside of human body systems. The novel coronavirus (SARS cov-2) has to cause 35 million infections and more than 1 million deaths worldwide as on October, 2020, according to the WHO dashboard. The explosive unfolds of SARS-CoV-2 indicate that a vaccine could be required to cease this global pandemic. Progress in SARS-CoV-2 vaccine improvement thus far has been faster than for some other pathogen in history. There were 42 vaccines in clinical research, and nearly 150 vaccines are in preclinical study. The immunogenicity alone data will help to attain a goal of design and development of good and safe vaccine averse to SARS CoV-2 infections in many countries and it also helps to predict the efficacy of the COVID-19 vaccine. Still now, we do not have a particular vaccine for COVID-19 infections, only we boost up our immune system to reduce the Covid-19 infections. So, we must know about our immune systems as well as the immunogenicity of the bio-active compounds for the prediction of the valuable and most powerful vaccine. A vaccine against SARS CoV-2 must control the infection and be capable of controlling the disease or transmission. For these reasons, we can detail explaining about fundamentals and application of Immunogenicity and also discuss its application to find out the potent SARS CoV-2-vaccine in this present study. 

Keywords: Covid-19, Immune system, SARS CoV-2, Vaccine.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy